ASH 2024 | suPar and GDF-15 are significantly associated with endothelial injury indices in CAR-T recipients
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, comments on the potential of soluble urokinase-type plasminogen activator receptor (suPAR) and growth differentiation factor-15 (GDF-15) as novel biomarkers for endothelial injury in CAR T-cell recipients. Dr Gavriilaki highlights that elevated suPAR and GDF-15 levels were significantly associated with endothelial injury indices in her patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Our abstract on suPAR and GDF levels, if we can say that these acronyms, has tried to find new markers for endothelial injury. Our group has focused on endothelial injury syndromes over the last year and among them, thrombotic microangiopathy is a very severe phenotype. So in our abstract, we measured suPAR and GDF in our patient population. We were able to show that both were increased compared to controls...
Our abstract on suPAR and GDF levels, if we can say that these acronyms, has tried to find new markers for endothelial injury. Our group has focused on endothelial injury syndromes over the last year and among them, thrombotic microangiopathy is a very severe phenotype. So in our abstract, we measured suPAR and GDF in our patient population. We were able to show that both were increased compared to controls. And suPAR has been also mentioned and measured in many patients with COVID-19. So that was the idea that we took over to our population. We have also managed to show significant associations with several disease markers with these indices. So in total we think that these are easily accessible markers and we need to investigate them more in our patient populations and see more long-term studies to predict outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sobi Pharmaceuticals: Honoraria; Sanofi Pharmaceuticals: Honoraria; Omeros Pharmaceuticals: Honoraria; AstraZeneca Pharmaceuticals: Honoraria; Jazz Pharmaceuticals: Research Funding.
